SEP-363856 hydrochloride

https://www.xunlan.net/web/image/product.template/180914/image_1920?unique=040deb5

¥ 12,500.90 12500.9 CNY ¥ 12,500.90

¥ 3,000.90

Not Available For Sale

规格或纯度 ≥99%
货号(SKU) S650186
品牌 阿拉丁
  • 包装

此组合不存在。

条款和条件
30天退款保证
运输:2-3 个工作日

规格


Cas Number 1310422-41-3
规格或纯度 ≥99%
纯度 ≥99%
包装 50mg10mg5mg

产品信息


品牌 阿拉丁
溶解性 H2O : 100 mg/mL (455.10 mM; Need ultrasonic) DMSO : 62.5 mg/mL (284.44 mM; Need ultrasonic)
过滤标签 5-HT Receptor,GPCR/G Protein,神经元信号传导
储存温度 2-8°C储存,干燥
运输条件 冰袋运输
生化和生理学机理 SEP-363856 hydrochloride(SEP-856 盐酸盐)是一种口服活性中枢神经系统活性精神药物,具有独特的非 D2/5-HT2A 作用机制,可发挥类似抗精神病药的作用。SEP-363856 盐酸盐(SEP-856 盐酸盐)具有以下功效
英文描述

SEP-363856 hydrochloride (SEP-856 hydrochloride), an orally active and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 hydrochloride (SEP-856 hydrochloride) has the potential for the study of schizophrenia

In Vitro

SEP-856 (10 μM) shows >50% inhibition of specific binding at α 2A , α 2B , D 2 , 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 2A , 5-HT 2B , 5-HT 2C , and 5-HT 7 receptors. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs . SEP-856 (0.3, 1 and 10 mg/kg, orally once) significantly reduces PCP-induced hyperactivity . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Acute treatment with phencyclidine (PCP), which induces robust hyperactivity in rodents . Dosage: 0.3, 1 and 3 mg/kg. Administration: Orally once. Result: Resulted in a dose-dependent inhibition of PCP-induced hyperactivity responses in C57Bl/6J mice (1-way ANOVA F (5, 59) = 18.96, p < 0.0001; Tukey’s post-hoc test, p < 0.05) with a 50% effective dose (ED 50 ) of approximately 0.3 mg/kg. Animal Model: Male Sprague Dawley rats . Dosage: 1, 2, and 5 mg/kg. Administration: I.V. injection. (Pharmacokinetic Analysis). Result: Rapidly absorbed with maximum plasma and brain concentrations reached within 0.25 to 0.5 hours in mice and rats and maximum plasma concentrations reached within 6 ± 2.83 hours in monkeys. Penetrated mouse and rat brains after oral administration (10 mg/kg), with average brain-to-plasma AUC ratios of ~3 respectively.

Form:Solid

IC50& Target:TAAR1 0.140 μM (EC 50 ) 5-HT 1A Receptor 2.3 μM (EC 50 ) 5-HT 1B Receptor 15.6 μM (EC 50 ) 5-HT 1D Receptor 0.262 μM (EC 50 ) 5-HT 2A Receptor >10 μM (EC 50 ) 5-HT 2C Receptor 30 μM (EC 50 ) 5-HT 7 Receptor 6.7 μM (EC 50 )

技术规格说明书


质检证书(CoA,COO,BSE/TSE)